Reactive oxygen species-responsive polymer drug delivery systems

Jiaxue Liu; Boyan Jia; Zhibo Li; Wenliang Li

doi:10.3389/fbioe.2023.1115603

Reactive oxygen species-responsive polymer drug delivery systems

Front Bioeng Biotechnol. 2023 Feb 2:11:1115603. doi: 10.3389/fbioe.2023.1115603. eCollection 2023.

Authors

Jiaxue Liu¹, Boyan Jia¹, Zhibo Li², Wenliang Li¹

Affiliations

¹ Jilin Collaborative Innovation Center for Antibody Engineering, Jilin Medical University, Jilin, China.
² Department of Cardiology, The Second Hospital of Jilin University, Changchun, China.

Abstract

Applying reactive polymer materials sensitive to biological stimuli has recently attracted extensive research interest. The special physiological effects of reactive oxygen species (ROS) on tumors or inflammation and the application of ROS-responsive polymers as drug-delivery systems in organisms have attracted much attention. ROS is a vital disease signal molecule, and the unique accumulation of ROS-responsive polymers in pathological sites may enable ROS-responsive polymers to deliver payload (such as drugs, ROS-responsive prodrugs, and gene therapy fragments) in a targeted fashion. In this paper, the research progress of ROS-responsive polymers and their application in recent years were summarized and analyzed. The research progress of ROS-responsive polymers was reviewed from the perspective of nanoparticle drug delivery systems, multi-responsive delivery systems, and ROS-responsive hydrogels. It is expected that our work will help understand the future development trends in this field.

Keywords: ROS-responsive; hydrogel; nanoparticle; reactive oxygen species (ROS); stimuli-responsive.

Publication types

Review

Grants and funding

This work was supported by a grant from, the Department of Education of Jilin province (Nos JJKH20200449KJ and JJKH20210479KJ), the Science and Technology Innovation and Development Projects of Jilin city (No. 20190601178), Jilin province Development and Reform Commission (No. 2021C039-3), the Innovation and Entrepreneurship Training Program for Undergraduates at Jilin Medical University (No. 202013706055), doctoral research start-up funding from Jilin Medical University (No. JYBS2019012), the Fundamental Research Funds for the Central Universities (Grant No. 2020-JCXK-14), and the Bethune Plan Project of Jilin University (Grant No. 2020B20).